Lorus reports LOR-2040 data

Lorus Therapeutics Inc. (TSX:LOR; OTCBB:LRUFD) said LOR-2040 plus high-dose cytarabine (HiDAC) led to a 28% rate of complete remission (CR) or CR with incomplete blood count recovery (CRi) in a Phase ...